GlassScriptPhysician profile
Hadeel Abdalla
NPI 1689105330
$1,710.40
in general payments reported to CMS, 2019-2025
19 companies · $821 in 2025
The $821 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $235 · 2024: $654 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $241.84 | 2024-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $226.77 | 2023-2025 | |
| Corcept Therapeutics | $169.62 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $156.24 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $125.00 | 2025 | |
| Dexcom, INC. | $110.16 | 2023-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $96.88 | 2023-2025 | Isturisa, Signifor Lar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.29 | 2024-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $76.27 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $75.58 | 2024 | |
| Novo Nordisk INC | $72.44 | 2024-2025 | Wegovy, Saxenda |
| Medtronic, INC. | $56.10 | 2023 | Minimed 780g |
| Insulet Corporation | $49.17 | 2025 | Omnipod |
| Abbott Laboratories | $48.53 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $42.10 | 2023 | Strensiq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $29.76 | 2025 | Rezdiffra |
| Tolmar, INC. | $26.02 | 2025 | Fensolvi |
| Cequr Corporation | $17.66 | 2025 | Cequr Simplicity |
| Amgen INC. | $13.97 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hadeel Abdalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.